<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293747</url>
  </required_header>
  <id_info>
    <org_study_id>0903/I/PRO</org_study_id>
    <nct_id>NCT01293747</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Injectable Estradiol and Progesterone Microspheres Suspension</brief_title>
  <official_title>Multiple-dose Pharmacokinetic Study of Two Aqueous Suspensions of Estradiol and Progesterone Microspheres (1 mg/20 mg &amp; 0.5 mg/15 mg) for Intramuscular Administration, in Postmenopausal Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Productos Científicos S. A. de C. V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Productos Científicos S. A. de C. V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I pharmacokinetic study

      Main objective:

      To determine plasmatic profiles and pharmacokinetic parameters of estradiol and progesterone
      on each of the formulations studied, after multiple-dose administration

      Study design:

      Randomized, controlled, open-label, parallel, pharmacokinetic study

      Sites: 1

      Subjects: 30 postmenopausal women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sites: 1

      Phase: 1

      Main objective:

      To determine plasmatic profiles and pharmacokinetic parameters of estradiol and progesterone
      on each of the formulations studied, after multiple-dose administration.

      Secondary objectives:

      To determine bioavailability of each of the formulations studied, after
      multiple-dose-administration. Describe tolerability of each of the formulations studied,
      after multiple-dose administration.

      Study design: Randomized, controlled, open-label, parallel, pharmacokinetic study

      Investigational Products:

        -  Estradiol and progesterone microspheres aqueous suspension (1 mg/20 mg)

        -  Estradiol and progesterone microspheres aqueous suspension (0.5 mg/15 mg)

      Study subjects: 30 postmenopausal women 45 - 65 years old

      Brief description: After written informed consent, 30 eligible women will be randomized to
      study treatments (one IM injection each 28 days, for a total of 4 doses). Blood samples will
      be obtained for pharmacokinetic study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>0 - 60 Days</time_frame>
    <description>Estrogen and progesterone plasma concentrations and pharmacokinetic parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>0 - 60 days</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability. Adverse events will be evaluated through periodic clinical evaluations and laboratory tests (comparison between enrollment and discharge).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Estradiol 0.5 mg/Progesterone 15 mg microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol 1 mg/Progesterone 20 mg microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol + Progesterone</intervention_name>
    <description>Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.</description>
    <arm_group_label>Estradiol 1 mg/Progesterone 20 mg microspheres</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol + Progesterone</intervention_name>
    <description>Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.</description>
    <arm_group_label>Estradiol 0.5 mg/Progesterone 15 mg microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  45 to 65 years old

          -  Able to read and write

          -  Postmenopausal

          -  Body Mass Index equal or below 34.99 kg/m2

          -  Healthy

          -  Normal uterus

          -  Time availability

        Exclusion Criteria:

          -  Hypersensitivity to progesterone or related compounds

          -  Hypersensitivity to estrogens

          -  Hysterectomy

          -  History or present hormone-dependent tumor

          -  History or present uterine cervix dysplasia

          -  Abnormal and clinically-significant laboratory test results

          -  Family history of breast cancer

          -  History of thromboembolic disease

          -  Non-controlled hypertension

          -  History of stroke

          -  History of cardiac valve surgery

          -  Renal failure

          -  Hepatic failure

          -  Non-controlled diabetes

          -  History of serious neurologic disease

          -  Reduced mobility

          -  Anemia

          -  Previous or concomitant hormone therapy

          -  Previous or concomitant therapy with inhibitors or inductors of cytochrome
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Bernardo, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)</name>
      <address>
        <city>Pachuca</city>
        <state>Hidalgo</state>
        <zip>42090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2011</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Productos Científicos S. A. de C. V.</investigator_affiliation>
    <investigator_full_name>Roberto Bernardo Escudero</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Estrogen</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Microspheres</keyword>
  <keyword>Menopause</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

